Resumo

COBIAN CABALLERO, Carlos Oliver; ACOSTA BROOKS, Soraida Cándida; MARTINEZ FERIA, Francisco  e  ROMERO GARCIA, Lázaro Ibrahim. Survival in patients with non-small cell lung cancer vaccinated with CIMAvax-EGF. MEDISAN [online]. 2016, vol.20, n.3, pp. 320-328. ISSN 1029-3019.

An observational, descriptive and cross-sectional study in a first moment, and cohort analytic in a second time, of 95 patients with non-small cell lung cancer in advanced stages, assisted at "Saturnino Lora Torres" Teaching Clinical Surgical Provincial Hospital and in 4 polyclinics of Santiago de Cuba, was carried out during the period 2006-2013, in order to estimate the survival in them after the vaccination with CIMAvax-EGF and to identify the factors associated to the mortality, for which Kaplan-Meier method and Cox regression were used, respectively. The global survival in 2 years was 20.7%, with a median of 13 months, as long as the survival a year after applying the vaccine was 36.5%. On the other hand, in the stage IIIB, the favorable response to the first line treatment, the chemotherapy-radiotherapy-vaccine combination and the immunization in 4 or more occasions, facilitated a significantly higher survival. The unfavorable reaction to the first therapeutic line constituted a prediction factor of death risk increase in the population affected

Palavras-chave : global survival; non-small cell lung cancer; cancer vaccine; CIMAvax-EGF.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )